Mark Parrington
14Patents
3h-index
22Co-inventors
56Inventor score
Filing activity: Sep 4, 1997 → Oct 2, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6060308A | RNA respiratory syncytial virus vaccines | Chemistry; Metallurgy | 57 | Expired |
| US7786278B2 | Modified CEA nucleic acid and expression vectors | Chemistry; Metallurgy | 16 | Active |
| US8207314B2 | Tumor antigens for prevention and/or treatment of cancer | Human Necessities | 13 | Active |
| US6428324B1 | RNA respiratory syncytial virus vaccines | Chemistry; Metallurgy | 3 | Expired |
| US8236776B2 | Modified CEA nucleic acid and expression vectors | Human Necessities | 1 | Active |
| US8021664B2 | Tumor antigens Bfa5 for prevention and/or treatment of cancer | Human Necessities | 1 | Expired |
| US7851213B2 | Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US6475780B1 | Alphavirus vectors for paramyxovirus vaccines | Chemistry; Metallurgy | 1 | Expired |
| US8911991B2 | Multi-antigen vectors of melanoma | Chemistry; Metallurgy | 1 | Active |
| US7220826B1 | Expressing gp140 fragment of primary HIV-1 isolate | Chemistry; Metallurgy | 0 | Expired |
| US9217158B2 | Replication-defective flavivirus vaccines and vaccine vectors | Emerging Cross-Sectional Technologies | 0 | Active |
| US8562970B2 | Modified CEA/B7 vector | Chemistry; Metallurgy | 0 | Active |
| US8530442B2 | Modified CEA nucleic acid and expression vectors | Human Necessities | 0 | Active |
| US8946174B2 | Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.